期刊文献+

糖尿病是可切除胰腺导管腺癌的预后因子 被引量:1

Type 2 diabetes mellitus is a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma
下载PDF
导出
摘要 目的:探讨合并2型糖尿病与胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)患者的临床病理因素及其与预后的关系。方法:回顾性分析2009年1月至2011年2月可手术切除PDAC患者的临床病理资料,进行生存分析。结果:136例PDAC患者中合并糖尿病的比率为27.9%,糖尿病与各临床病理特征均无关(均P>0.05)。单因素分析显示:糖尿病、肿瘤最大直径、组织学分化程度、pT分期、脉管侵润及pTNM分期,均与PDAC患者预后显著相关(均P<0.05)。多因素分析显示:合并糖尿病(HR,1.873;P=0.007),组织学低分化肿瘤(HR=2.647;P=0.002)及肿瘤最大直径≥4.0 cm(HR=1.699;P=0.018),均是独立预后因子。结论:合并糖尿病是可手术切除的PDAC患者预后差的独立预测因子。 Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal human cancers. Current studies on the relationship between complicated type 2 diabetes mellitus (T2DM) and PDAC prognosis have demonstrated inconsistent results. The present study aimed to determine the relationship between complicated T2DM and the clinicopathological characteristics of PDAC, and evaluate whether complicated T2DM is a significant predictor for overall survival in patients with resectable PDAC. Methods: In this study, clinicopathological characteristics were observed in 136 patients who underwent surgery for PDAC at the Shengjing Hospital of China Medical University between January 2009 and February 2011. The relationship between complicated T2DM and overall survival of PDAC patients was analyzed using univariate and multivariate analyses. Results:The median age of patients was 60 years (range: 35-80 years). Among the 136 patients, 76(55.9%) were male. The prevalence of complicated T2DM was 27.9%in 136 PDAC cases. Preexisting T2DM was not associated with any of the clinicopathological characteristics (all P〉0.05). Univariate analysis showed that complicated T2DM (P=0.045), maximum diameter (P=0.011), histological differentiation (P=0.013), pT stage (P=0.034), vessel invasion (P=0.032), and pTNM stage (P=0.030) were significantly associated with the overall survival of PDAC patients. The median overall survival time was 14.2 months for T2DM patients, and 18.8 months for non-T2DM patients. In multivariate analysis, complicated T2DM [hazard ratio (HR), 1.873;95%confidence interval (CI), 1.187-2.954;P=0.007], poorly differentiated tumor (HR, 2.647;95%CI, 1.413-4.957;P=0.002), and maximum diameter≥4.0 cm (HR, 1.699;95%CI, 1.094-2.640;P=0.018) were the independent predictors associated with poor overall survival. Conclusion:Complicated T2DM was associated with poor prognosis. It could be used as a prognostic predictor in patients with resectable PDAC. If confirmed, these findings may provide a novel approach for individualized adjuvant therapy.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2014年第15期979-983,共5页 Chinese Journal of Clinical Oncology
关键词 胰腺导管腺癌 2型糖尿病 预后 总生存期 pancreatic ductal adenocarcinoma type 2 diabetes mellitus prognosis overall survival
  • 相关文献

参考文献18

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Can- cerJ Clin, 2008, 58(2):71-96.
  • 2Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a po- tential due to the early diagnosis of pancreatic cancer[J]. Lancet On- col, 2009, 10(1):88-95.
  • 3WinterJM, CameronJL, Campbell K.A, et al. 1423 pancreaticoduo- denectomies for pancreatic cancer: a single-institution experience [J].J Gastroimest Surg, 2006, 10(9):1199-1210.
  • 4Zyromsld NJ Mathur A, Pitt HA, et al. Obesity potentiates the growth and dissemination of pancreatic cancer[J]. Surgery, 2009, 146 (2) :258-263.
  • 5Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes meUitus.in pancreatic cancer compared to common cancers[J]. Pancreas, 2013, 42(2):198-201.
  • 6Chu CK, Mazo AE, Goodman M, et al. Preoperative diabetes melli- ms and long-term survival after resection of pancreatic adenocarci- noma[J]. Ann Surg Oncol, 2010, 17(2) :502-513.
  • 7Nakata B, Ishikawa T, Amano R, et al. Impact of preoperative dia- betes meUitus on clinical outcome after pancreatectomy[J]. Int J Surg, 2013, 11(9):757-761.
  • 8Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mor- tality in cancer patients with preexisting diabetes meUitus: a system- atic review and meta-analysis[J].JAMA, 2008, 300(23):2754-2764.
  • 9Sperti C, Pasquali C, Piccoli A, et al. Survival after resection for ductal adenocarcinoma of the pancreas[J]. Br J Surg, 1996, 83(5): 625-631.
  • 10Coughlin SS, Calle EE, Patel AV, et al. Predictors of pancreatic can- cer mortality among a large cohort of United States adults[J]. Can- cer Causes Control, 2000, 11(10):915-923.

二级参考文献1

共引文献12

同被引文献14

  • 1季尚玮,刘克辉,王江滨.糖尿病与胰腺癌的关系探讨[J].中国实用内科杂志,2007,27(21):1686-1688. 被引量:13
  • 2Jemal A,Siegel R, Ward E,et al. Cancer statistics[J]. CA Canc- er J Clin,2008,58(2) :71.
  • 3Ben Q,Xu M,Ning X,et al. Diabetes mellitus and risk of pancre- atic cancer:a meta-analysis of cohort studies [J]. Eur J Cancer, 2011,47(13) :1928.
  • 4Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glu? cose stimulate cell proliferation in MCF-7 human breast :ancer cells:reciprocal involvement of PKC-alpha and PPAR ex- pression[J]. Bioehim Biophys Aeta, 2002,1592(2) : 107.
  • 5Gapsturs M, Gammp H, Lowe W, et al. Abnormal glucose metab- olism and pancreatic cancer mortality[J]. JAMA, 2000,283 (19): :552.
  • 6Stolzenberg-Solomon RZ, Grauhard BI, Chari S, et al. Insulin, glu- zose insulin resistance and pancreatic cancer in male smoker[J]. lAMA, 2005,294(22) :2872.
  • 7Bowker SL,Johnson JA. Prospective study of hyperglycemia and cancer risk[J]. Diabetes Care, 2007,30(3) : 561.
  • 8Huxley R, Ansary-Moghaddam A,Berrington de Gonzdlez A, et al. Type-II diabetes and pancreatic cancer~ a meta-analysis of 36 studies[J]. Br J Cancer J Clin,2010,60(2) :207.
  • 9Chati ST,Leibson CL,Rabe KG, et al. Pancreatic cancer associ- ated diabetes ellitus., prevalence and temporal association with diagnose of cancer[J]. Gastroentrology, 2008,134(1) : 95.
  • 10廖日红.糖尿病患者罹患胰腺癌调查分析[J].中国卫生产业,2013,10(20):26-27. 被引量:5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部